Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Non-Current Assets (2023 - 2025)

Contineum Therapeutics has reported Non-Current Assets over the past 3 years, most recently at $5.9 million for Q3 2025.

  • Quarterly results put Non-Current Assets at $5.9 million for Q3 2025, up 564.42% from a year ago — trailing twelve months through Sep 2025 was $24.6 million (up 190.32% YoY), and the annual figure for FY2024 was $6.5 million, up 141.01%.
  • Non-Current Assets for Q3 2025 was $5.9 million at Contineum Therapeutics, down from $6.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CTNM hit a ceiling of $6.5 million in Q4 2024 and a floor of $891000.0 in Q3 2024.
  • Median Non-Current Assets over the past 3 years was $4.9 million (2024), compared with a mean of $4.1 million.
  • Peak annual rise in Non-Current Assets hit 564.42% in 2025, while the deepest fall reached 59.1% in 2025.
  • Contineum Therapeutics' Non-Current Assets stood at $2.7 million in 2023, then surged by 141.01% to $6.5 million in 2024, then dropped by 8.34% to $5.9 million in 2025.
  • The last three reported values for Non-Current Assets were $5.9 million (Q3 2025), $6.0 million (Q2 2025), and $6.1 million (Q1 2025) per Business Quant data.